Vaz-Luis et al. evaluated 3394 patients with HER2-positive breast cancer and could show that hormone receptor-negative HER2-positive patients were more likely to have recurrence in the brain compared to hormone receptor-positive HER2-positive patients [23]. This evidence concerns the gene ERBB2 and breast cancer.